Yes, diclofenac carries significant cardiovascular risk and should be avoided or used with extreme caution.
Diclofenac is associated with a 50-60% increased risk of major adverse cardiovascular events (MACE) compared to non-use, including myocardial infarction, stroke, and cardiac death, with risks comparable to withdrawn COX-2 inhibitors like rofecoxib. 1
Magnitude of Cardiovascular Risk
The American Heart Association guideline data demonstrates diclofenac's particularly concerning risk profile among NSAIDs 1:
- Vascular events: RR 1.63 (95% CI 1.12-2.37) vs placebo in RCTs
- CV events/MI: RR 1.40 (95% CI 1.16-1.70) in observational studies
- Recurrent MI: RR 1.54 (95% CI 1.23-1.93) in registry data
- Mortality: RR 2.40 (95% CI 2.09-2.80) - more than doubling death risk
These risks exceed those of ibuprofen and are substantially higher than naproxen, which shows neutral cardiovascular effects.
FDA Black Box Warning
The FDA drug label carries a black box warning stating: "NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk." 1 Diclofenac is contraindicated for perioperative pain in CABG surgery.
Recent Evidence Confirms Risk Across All Doses
The most recent 2023 Danish nationwide study found no dose-dependent safety advantage 2:
- High-dose diclofenac (≥150 mg/day): IRR 1.55 (95% CI 1.40-1.71)
- Low-dose diclofenac (<150 mg/day): IRR 1.52 (95% CI 1.41-1.63)
- Head-to-head comparison showed no difference (IRR 1.01,95% CI 0.90-1.12)
This definitively refutes the assumption that low-dose diclofenac is cardiovascularly safe. The risk appears within 30 days of initiation and persists regardless of dose.
Comparative Risk with Other NSAIDs
A 2022 head-to-head comparison study 3 found:
- 20% higher MACE risk vs other older COX-2 inhibitors (meloxicam/etodolac): aIRR 1.19 (95% CI 1.10-1.28)
- 57% higher cardiac death risk vs meloxicam/etodolac: aIRR 1.57 (95% CI 1.21-2.03)
- Equivalent risk to newer coxibs (celecoxib/etoricoxib): aIRR 0.96 (95% CI 0.85-1.08)
The 2018 Danish cohort study 4 involving over 6 million person-years confirmed:
- 50% increased risk vs non-initiators (IRR 1.5,95% CI 1.4-1.7)
- 20% increased risk vs ibuprofen or paracetamol (IRR 1.2,95% CI 1.1-1.3)
- 30% increased risk vs naproxen (IRR 1.3,95% CI 1.1-1.5)
Risk Stratification by Patient Population
Highest absolute risk occurs in patients with:
- Previous myocardial infarction
- Heart failure
- High baseline cardiovascular risk
Highest relative risk paradoxically appears in:
- Healthy individuals with low baseline cardiovascular risk 4
- Women (aIRR 1.28,95% CI 1.15-1.43) 3
- Patients with headache as indication (IRR 5.10,95% CI 1.46-17.85) 2
Critical Clinical Pitfalls
Therapeutic anticoagulation does not protect: A 2025 case report 5 documented anterior STEMI in a 34-year-old with mechanical valve on therapeutic warfarin (INR 3.17) nine days after starting diclofenac, demonstrating that anticoagulation cannot prevent platelet-driven thrombotic events from NSAIDs.
Risk begins immediately: Cardiovascular events occur within 30 days of initiation, not just with chronic use 2, 4.
No safe dose exists: Both high and low doses carry equivalent risk 2.
Concomitant risks: Diclofenac also increases upper GI bleeding 4.5-fold vs non-use and 2.5-fold vs ibuprofen/paracetamol 4.
Clinical Recommendations
Avoid diclofenac in patients with:
- Any cardiovascular disease or prior events (absolute contraindication per FDA) 6
- Cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking)
- Heart failure (avoid unless benefits clearly outweigh risks) 6
- Concurrent anticoagulation 5
If diclofenac must be used:
- Use lowest effective dose for shortest duration possible 6
- Monitor blood pressure throughout treatment 6
- Avoid in perioperative CABG setting (absolute contraindication) 1, 6
- Consider naproxen as safer alternative (neutral CV profile) 1
Preferred alternatives with lower cardiovascular risk:
- Naproxen (RR 0.92-0.97 for vascular events) 1
- Ibuprofen (lower risk than diclofenac, though not risk-neutral)
- Paracetamol for mild-moderate pain
The evidence consistently demonstrates that diclofenac carries cardiovascular risks comparable to withdrawn drugs like rofecoxib, exceeding those of other traditional NSAIDs, with no dose at which it becomes safe.